Approval spans early and levodopa-treated disease; a 6-week titration and CYP3A interactions put pharmacists at the center of starting therapy.

In an interview with Pharmacy Times, City of Hope researchers discuss a preclinical platform designed to redirect CAR T cells after infusion and how pharmacists could help bring this adaptable approach into clinical practice.

Pharmacists can explain the evidence supporting the intramuscular injection, address specific concerns, and help families understand what is known—and what is not known—about oral vitamin K.

William J. Peppard, PharmD, explains how emerging suzetrigine findings after knee arthroplasty connect opioid stewardship with functional recovery and the pharmacist’s role in ensuring treatment access.

In an interview with Pharmacy Times, LINKER-SMM1 study investigator Paula Rodríguez-Otero, MD, PhD, a hematologist at Clínica Universidad de Navarra in Pamplona, Spain, explains how researchers selected high-risk patients and how she weighs infections against the potential to prevent progression to active disease.

September’s pain management coverage examined postoperative nonopioid options, lessons from sickle cell pain research, and pharmacists’ experiences with controlled-substance prescribing.

FDA clears tiratricol for MCT8 deficiency, lowering dangerous T3 and outlining dosing, lab testing, and pharmacy access.

A single infusion reversed new-onset type 1 diabetes (T1D) in more than half of treated mice by strengthening regulatory T cells and driving autoreactive CD8+ T cells into a less destructive state.